Human Albumin Kedrion (Human Albumin Solution)

Human Albumin Kedrion is employed in clinical settings where rapid restoration of intravascular volume is required.

• Management of hypovolemia due to acute blood loss or trauma.
• Support for patients with severe burns to maintain circulatory stability.
• Treatment of hypoalbuminemia associated with liver disease, nephrotic syndrome, or malnutrition.
• Adjunct therapy during major surgery to counteract fluid shifts.
• Volume replacement in patients with septic shock when colloid support is indicated.

• Human Albumin Kedrion provides exogenous albumin that contributes to plasma oncotic pressure. Albumin molecules bind water and small solutes, drawing fluid from the interstitial space into the vascular compartment. By increasing colloid osmotic pressure, the solution expands intravascular volume, improves hemodynamic stability, and supports tissue perfusion. The effect is mediated through physical osmotic forces rather than receptor‑mediated pharmacology in clinical practice.

Adverse reactions to Human Albumin Kedrion are generally infrequent but may occur following intravenous administration and may vary with patient condition.

Common

• Mild fever or chills occurring shortly after infusion.
• Transient headache that resolves without intervention.
• Nausea or vomiting during or shortly after the infusion.
• Localized erythema, warmth, or swelling at the infusion site.
• Mild hypotension that resolves spontaneously.

Serious

• Anaphylactic or severe allergic reaction, characterized by urticaria, bronchospasm, hypotension, or angioedema.
• Acute hemolysis manifested by sudden drop in hemoglobin and hemoglobinuria.
• Volume overload leading to pulmonary edema, manifested by dyspnea, crackles, and reduced oxygen saturation.
• Thrombotic events such as deep vein thrombosis.

Before using Human Albumin Kedrion, clinicians should evaluate patient history and monitor for potential risks.

• Assess for known hypersensitivity to human albumin or any plasma‑derived products.
• Evaluate fluid status and cardiac function to avoid volume overload.
• Use caution in patients with renal or hepatic impairment, as albumin metabolism may be altered.
• Monitor vital signs and laboratory parameters during and after infusion.
• Consider the risk of infection transmission, although the product undergoes viral inactivation steps.
• Avoid use in patients with uncontrolled hypertension without appropriate monitoring.

Human Albumin Kedrion may interact with other intravenously administered agents, influencing efficacy or safety. Therefore, reviewing the patient's medication regimen is recommended.

Avoid

• Concurrent administration with high‑dose diuretics that may exacerbate intravascular volume depletion.
• Co‑infusion with blood products containing incompatible antibodies, risking hemolytic reactions.

Use with caution

• Simultaneous use of vasopressors; monitor hemodynamic response closely.
• Combination with anticoagulants; observe for signs of bleeding due to volume shifts.
• Administration with other colloid solutions; assess total oncotic load to prevent overload.
• Use with nephrotoxic drugs; monitor renal function as volume changes may affect drug clearance.